← All trials
NCT00677339
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2008
- Primary completion
- Feb 1, 2010
- Completion date
- May 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Menzies School of Health ResearchLead sponsor
- Menzies School of Health ResearchOverall official - principal investigator
- District Ministry of Health, TimikaOverall official - principal investigator
- Papuan Community Health and Development FoundationOverall official - principal investigator
- Mimika District Health AuthorityOverall official - principal investigator
- Australian Capital Territory Department of HealthOverall official - principal investigator
- Institute of Medical and Veterinary Pathology, South AustraliaOverall official - principal investigator
- University of MelbourneOverall official - principal investigator
- Menzies School of Health ResearchStudy director
- National Health and Medical Research Council, AustraliaOverall official - principal investigator
- National Institute of Health Research and Development, Jakarta, IndonesiaOverall official - principal investigator
- Australian National UniversityCollaborator
- National Institute of Health Research and Development, Jakarta, IndonesiaCollaborator
- Menzies School of Health ResearchReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.